Atlas Trials

Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic

Clinical trial NCT02972320 · UNKNOWN

Trial details

NCT number
NCT02972320
Sponsor
Yunpeng Liu
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Extensive Stage Small Cell Lung Cancer
Start date
2016-06-01
Primary completion
2017-12-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.